THE PROGNOSTIC VALUE OF PHARMACOLOGICAL AND GENETIC TESTING IN MEDICAL THERAPY OF AGE-RELATED MACULAR DEGENERATION

THE PROGNOSTIC VALUE OF PHARMACOLOGICAL AND GENETIC TESTING IN MEDICAL THERAPY OF AGE-RELATED MACULAR DEGENERATION

The review presents the analysis and possible ways of solving the issues of treatment of age related macular degeneration (AMD) based on pharmacogenetic approaches. The AMD problem is relevant because of the growing number of resistant neovascular membranes, an increase in the number of older-age pa...

Full description

Bibliographic Details
Main Authors:	N. A. Bakunina, S. N. Shcherbo, L. N. Kolesnikova
Format:	Article
Language:	Russian
Published:	Real Time Ltd 2018-10-01
Series:	Российский офтальмологический журнал
Subjects:	возрастная макулярная дегенерация фармакогенетика анти-vegf терапия полиморфизмы генов age-related macular degeneration pharmacogenetics anti-vegf therapy genes polymorphisms
Online Access:	https://roj.igb.ru/jour/article/view/156

Similar Items

Efficacy of aflibercept in patients with neovascular age-related macular degeneration when combined with cataract surgery
by: A. A. Kuznetsov, et al.
Published: (2018-10-01)

The role of complement system and other inflammatory factors in the development of age-related macular degeneration
by: E A Abdulaeva
Published: (2018-08-01)

The Effectiveness of Retinalamin® Administered by Various Intramuscular Injection Timings in the Treatment of Patients with the Dry Form of Age- Related Macular Degeneration
by: V. V. Neroev, et al.
Published: (2018-10-01)

Pathogenetic issues of retinal dystrophies associated with myopia and agerelated macular degeneration
by: I. B. Alekseev, et al.
Published: (2018-10-01)

Combined modality therapy for exsudative form of age-related macular degeneration
by: М. V. Budzinskaya, et al.
Published: (2013-01-01)

Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degeneration
by: F. A. Bakhritdinova, et al.
Published: (2018-10-01)

The results of a long-term follow up of patients with age-related macular degeneration who received a lutein-containing medication
by: O. V. Zaytseva, et al.
Published: (2018-10-01)

ASPECTS OF LIPID-LOWERING THERAPY WITH ATORVASTATIN IN PATIENTS WITH MYOCARDIAL INFARCTION FROM THE PERSPECTIVE OF PERSONALIZED MEDICINE
by: M. V. Solodun, et al.
Published: (2015-09-01)

Генетические маркеры риска развития спектра метаболических нарушений при применении антипсихотиков второй генерации
by: Мазо, Г.Э., et al.
Published: (2017-12-01)

The importance of pharmacogenetic research for optimization of antihypertensive treatment
by: O V Shevchenko, et al.
Published: (2012-09-01)

Клиническая фармакогенетика: тернистый путь внедрения в клиническую практику
Published: (2018-06-01)

Clinical effectiveness of nutrof total supplement for Dry age-related macular Degeneration
by: E. N. Eskina, et al.
Published: (2018-10-01)

Рекомендации по применению фармакогенетического тестирования в клинической практике
Published: (2018-06-01)

Роль генетического полиморфизма в онкологии
Published: (2018-06-01)

Functional express testing and self monitoring in the diagnosis and treatment of macular diseases
by: S. O. Milyutkina, et al.
Published: (2018-10-01)

Clinical and genetic characteristics of treatment-resistant asthma
by: V. I. Trofimov, et al.
Published: (2013-12-01)

Monitoring post-approval drug safety in pregnancy: pharmacogenetic aspects
Published: (2018-02-01)

Фармакогенетические аспекты эффективности терапии клозапином при фармакорезистентной шизофрении
by: Кравцов, В.В., et al.
Published: (2019-09-01)

Фармакогенетика аминогликозидной тугоухости
Published: (2018-06-01)

Efficacy and safety of medicines: the value and opportunities of clinical pharmacology
by: M. V. Zhuravleva, et al.
Published: (2018-02-01)

Сочетание алкогольнойзависимости и депрессии:трудности и особенности терапии
by: Николишин, Е., et al.
Published: (2017-08-01)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
by: Kabanarou SA, et al.
Published: (2017-05-01)

Перспективы для клинического фармаколога
Published: (2018-06-01)

PHARMACOGENETIC TESTING OPPORTUNITIES IN CARDIOLOGY BASED ON EXOME SEQUENCING
by: N. V. Shcherbakova, et al.
Published: (2015-09-01)

Cost-effectiveness of intravitreal therapy in Age-Related Macular Degeneration
by: Piergiorgio Neri, et al.
Published: (2014-12-01)

Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration
by: Mohamed Kamel Soliman, et al.
Published: (2021-09-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Targeted therapy in age-related macular degeneration (AMD)
by: Klaudia Daria Szumna, et al.
Published: (2020-03-01)

APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY
by: D. A. Sychev, et al.
Published: (2015-09-01)

NETWORK APPROACH TO ANALYSIS OF QUANTITATIVE TRAIT LOCI FOR TUMOR NECROSIS FACTOR (TNFα-863, TNFα-308, TNFα-238), VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF-2578, VEGF+936) AND MATRIX METALLOPROTEINASE (ММР2-1306, ММР3-1171, ММР9-1569) GENES IN AGERELATED MACULAR DEGENERATION
by: A. V. Shevchenko, et al.
Published: (2017-10-01)

Recent developments in age-related macular degeneration: a review
by: Al-Zamil WM, et al.
Published: (2017-08-01)

Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab
by: Lucia Gonzalez-Buendia, et al.
Published: (2017-08-01)

Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration
by: Pelin Kıyat, et al.
Published: (2021-06-01)

The burden of neovascular age-related macular degeneration: a patient’s perspective
by: Spooner KL, et al.
Published: (2018-12-01)

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
by: Spooner K, et al.
Published: (2017-01-01)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
by: Dervenis N, et al.
Published: (2016-06-01)

Pharmacogenetic aspects of oral hypoglycemic therapy. Response and failure phenotypes
by: Y. A. Sorokina
Published: (2015-12-01)

Pharmacogenetics of antiepileptic drugs (literature review)
by: E. . Bochanova
Published: (2018-05-01)

Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration
by: Avaylon J, et al.
Published: (2020-05-01)

Clinical trials in pregnancy: evaluation of benefit/risk?
by: E. A. Sokova, et al.
Published: (2018-02-01)